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Abstract We present for the first time experimental evidence 
that in vitro synthesized RNA (eRNA) is trans-splieed after 
mieroinjection into the nuclei of mammalian tissue culture cells. 
The template used for cRNA synthesis was the early SV40 
BstXl/BamHI DNA fragment. This DNA fragment encodes 
exclusively for the second T-antigen exon and contains the intact 
small t-antigen intron. To generate the corresponding mRNA 
(TI-mRNA) by trans-splicing, the cells utilize a 5' cryptic splice 
site located within the second T-antigen exon of one cRNA 
molecule which is spliced to the small t-antigen 3' splice site of 
another cRNA molecule. Formation of the TI-mRNA by trans- 
splicing was confirmed by RT-PCR analysis and DNA sequenc- 
ing. Efficient trans-splicing required that competitive small t- 
antigen cis-splicing be inhibited by deletion of the small t-antigen 
5' splice site. The TI-mRNA was not generated when the cryptic 
5' splice site was mutated. 
Key words: SV40 Tl-antigen; Pre-mRNA synthesis; 
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I. Introduction 
In eukaryotic ells, the majority of the RNA polymerase II 
transcripts contain introns which are removed from the pre- 
mRNA molecules by the splicing machinery before nuclear 
export occurs. Joining different RNA segments together by 
alternative cis-splicing, multiple protein isoforms can be gen- 
erated from one type of pre-mRNA (for review, see [1]). Splice 
sites are not only essential to ensure correct intramolecular 
cis-splicing, they are also used to join segments from inde- 
pendent transcripts together by means of trans-splicing. Cis- 
splicing and trans-splicing have the same consensus sequences, 
utilize the same splicing machinery and form branched inter- 
mediates. Up to now trans-splicing has been demonstrated in 
lower eukaryonts (e.g. trypanosomes, nematodes, trematodes), 
where an untranslated small leader (SL) RNA is trans-spliced, 
providing the cap structure for each mRNA. Intermolecular 
RNA splicing has also been observed in plant cell organelles, 
where new mRNA molecules are formed by self-splicing with- 
out the participation of any U snRNPs (for review, see [24]). 
Furthermore, it has been shown in vitro that Saccharornyces 
cerevisiae and HeLa cell extracts catalyze the trans-splice re- 
action [5-8]. Although predicted by computer analysis [9] and 
suggested in several earlier reports [5,7,10-12], only recently 
has conclusive xperimental evidence been obtained that in- 
tact mammalian cells also have the potential to perform RNA 
trans-splicing and that the corresponding mRNA is translated 
into a functional protein [8]. By deletion of the first SV40 T- 
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antigen exon it was shown that rat cells transformed by an 
early SV DNA fragment (BstXI/BamHI) generate an SV40- 
specific mRNA (TI-mRNA) which is 147 nt larger than the 
primary transcript. Sequencing experiments revealed that the 
cells create the TI-mRNA by a trans-splice reaction between 
two identical Bst/Bam pre-mRNA molecules. During this 
trans-splicing process a cryptic 5' splice site, located within 
the second T-antigen exon of one pre-mRNA molecule (A), 
is combined with the conventional small t-antigen 3' splice site 
of a second pre-mRNA (B), as is illustrated in Fig. 1. There- 
fore, the TI-mRNA translation product, the Tl-antigen, is 
composed of two distinct SV40 T-antigen segments, a prox- 
imal segment with the amino acid sequence 109 131 provided 
by the pre mRNA molecule (A) and a distal segment with the 
amino acid sequence 83-708 provided by the pre-mRNA mol- 
ecule (B). The pre-mRNA molecules that are not engaged in 
trans-splicing are subjected to small t-antigen cis-splicing and 
translated into the T2 antigen. Since translation of the T2- 
mRNA starts with the first AUG in reading frame, the T2- 
antigen contains only the T-antigen amino acid sequence 109- 
708 and lacks the first 29 amino acids of the second T-antigen 
exon present in the Tl-antigen [8,13]. 
Since it is possible to analyze mRNA maturation and trans- 
lation efficiently in microinjected mammalian tissue culture 
cells [14,15] we combined in the present investigation i vitro 
pre-mRNA synthesis and in vivo mRNA processing to en- 
tirely exclude DNA rearrangement as a possible alternative 
mechanism to trans-splicing. The Bst/Bam pre-mRNA 
(cRNA) was synthesized in vitro and microinjected into the 
nuclei of TC7 and rat 2 cells. Immunofluorescence staining, 
RT-PCR and DNA sequencing experiments revealed that the 
injected cRNA was trans-spliced after nuclear injection and 
translated into the Tl-antigen. 
2. Materials and methods 
2.1. DATA constructs 
The p14-T7 DNA was obtained by inserting the early SV40 BstXl/ 
BamHI (Bst/Bam) 2.2 kb DNA segment into the multiple cloning site 
(AccI/BamHI) of pSPT19 DNA (Pharmacia), oriented in the same 
sense as the T7 promoter within the plasmid. The pl4A5't-T7 DNA 
was constructed by eliminating the consensus sequence (G/GTA chan- 
ged to G/CGC) of the small t-antigen 5' splice site of the p14-T7 
DNA by site-directed mutagenesis a  described elsewhere [8]. 
2.2. cRNA synthesis 
For runoff cRNA synthesis [16], the p14-T7 DNA and the pl4A5't- 
T7-DNA were linearized by Sinai which cuts 6 bp downstream from 
the BamHI site; completeness of the cleavage was confirmed by 
Southern blot analysis. In vitro transcription i cluding 1 ~tg of line- 
arised template DNA, the cap nucleotide m7G(5')ppp(5')G (Ambion) 
and T7 polymerase (T7 Cap-Scribe; Boehringer Mannheim) was per- 
formed according to the supplier's protocol. The quality and correct 
size of the cRNA preparations were confirmed by Northern blot anal- 
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ysis. The absence of any template DNA in the cRNA preparation 
after RQ-I-DNase (Promega) digestion was confirmed by PCR ana- 
lysis with 1 ng cRNA, the SV40 specific primers d (5'GAAATGC- 
CATCTAGTGAT3') and b (5'GTTATGATTATAACTGTTATGY) 
and 3 U Taq polymerase (BRL) after 35 PCR cycles (30 s at 94°C, 30 
s at 53°C, 1 min at 74°C each cycle). Control PCRs included 1 ng 
reverse-transcribed (RT) cRNA. The Southern blots were hybridized 
with a2P-labelled SV40 DNA [18]. 
2.3. cRNA injection and immunofluorescence staining 
Cells grown on glass slides [15] were microinjected with capped or 
non-capped cRNA molecules (concentration 1 gg/gl, injection volume 
10 s gl/cell) and stained for T-antigen as described previously [16]. 
The cRNA was subjected to agarose gel electrophoresis under dena- 
turing conditions (formamide/formaldehyde buff r) and processed for 
Northern blotting as described elsewhere [17,18]. 
3. Results and discussion 
3.1. In vitro cRNA synthesis 
In previous tudies we have demonstrated that microinjec- 
tion is a powerful tool for analyzing the function of biologi- 
cally relevant macromolecules directly in intact mammalian 
tissue culture cells [14,15]. One of the results we obtained 
was that in-vitro-synthesized arly SV40 RNA (cRNA) is 
cis-spliced and translated into wt T-antigen after intranuclear 
injection [16,17,19-21]. Subsequently, Xenopus oocytes were 
also used as recipients to study RNA processing and nuclear 
RNA export [22 26]. To investigate whether the in-vitro- 
synthesized pre-mRNA (cRNA) molecules are trans-spliced 
in mammalian cells, the early SV40 Bst/Bam DNA fragment 
was inserted into the multiple cloning site of the pSPT19 
DNA in the sense orientation with regard to the T7 promoter 
(p14-T7). As shown in Fig. 1B, the Bst/Bam DNA encodes 
only for the second T-antigen exon and contains the intact 
small t-antigen intron (66 nt). Before in vitro transcription by 
the T7 RNA polymerase (T7 Cap-Scribe, Boehringer), the 
p14-T7 template DNA was linearized by SmaI endonuclease 
treatment which cuts 6 bp downstream from the BamHI site. 
Synthesis of the cRNA started with the formation of the cap 
structure and the runoff transcript (cap-Bst/Bam-cRNA) was 
liberated from the template DNA by two consecutive DNase 
treatments [16]. The size of the cRNA was determined by 
Northern blot analysis. As shown in Fig. 2A (lane 1), a single 
transcript of about 2.2 kb was obtained, which was the size 
predicted from the Bst/Bam template DNA. To verify the 
absence of the template DNA, the cRNA was subjected to 
PCR analysis using the SV40 specific primer pair d and b for 
DNA amplification (Fig. 2A). These primers bind within the 
coding region of the second exon of the large T-antigen and 
are at a distance of 258 bp from each other on the SV40 DNA 
(Fig. 1B). As shown in Fig. 2, no SV40-specific PCR product 
was obtained when the reverse transcription was omitted, ex- 
cluding the contamination of the cRNA preparation with 
trace amounts of the template DNA (Fig. 2B, lane 1). As 
expected, the 258 bp DNA fragment was generated when 
the cRNA was subjected to RT-PCR analysis (Fig. 2B, lane 
2). 
3.2. The cRNA is trans-spliced and translated into the 
Tl-antigen after intranuclear microinjeetion 
In a first set of experiments, synthesis of SV40-specific pro- 
teins was analyzed by immunofluorescence staining after in- 
tranuclear injection of the cap-Bst/Bam-cRNA into TC7 and 
rat 2 cells. To demonstrate hat the cRNA was processed into 
mRNA and translated in vivo, the cells were fixed and stained 
at different points in time after the cRNA injection. The anti- 
bodies used were a hamster polyclonal antibody (HPA), which 
recognizes both the Tl-antigen and the T2-antigen, and a 
monoclonal antibody (Ab-2; Oncogene Science) that specifi- 
cally recognizes an epitope within the T-antigen amino acid 
sequence 83-108; this epitope is present in the Tl-antigen but 
not in the T2-antigen (Fig. 1C,E). In both cell types, T-anti- 
gen synthesis was already demonstrable 30min after injection, 
with the maximum number of T-antigen positive cells being 
obtained 5 6 h after cRNA transfer. At this time, more than 
half of the injected cells exhibited strong intranuclear T-anti- 
gen fluorescence after staining with the HPA-antibody. How- 
ever, only 3 5% of these cells were Tl-antigen-positive when 
stained with the Ab-2 antibody (Table 1). This demonstrates 
that the injected cells preferentially synthesized the T2-anti- 
gen. With prolonged cultivation time of the microinjected 
cells, the number of positive cells and the intensity of the T- 
antigen-specific luorescence decreased, and about 36 h after 
injection the cells were once again T-antigen egative. 
In an earlier investigation [8,13] we demonstrated that the 
efficiency of Tl-antigen synthesis increased significantly in 
stable transformed rat cells that carry the pl4-A5't DNA as 
a trans-gene. The pl4-A5't construct contains the early SV40 
Bst/Bam DNA fragment but the cells cannot excise the small 
t-antigen intron, since the small t-antigen 5' splice site was 
deleted from the Bst/Bam DNA fragment by site-directed mu- 
tagenesis before microinjection. Small t-antigen cis-splicing 
and TI-mRNA formation by trans-splicing are in competi- 
tion, because both splice reactions utilize the same 3' splice 
acceptor site. 
To confirm that the trans-splice efficiency also increases 
when the in-vitro-synthesized cRNA molecules carry the 
above deletion, the early SV40 Bst/BamA5't DNA fragment 
was inserted into the multiple cloning site of the pSPT19 
DNA (pl4-A5't-T7) for in vitro cRNA synthesis (cap-Bst/ 
BamA5't-cRNA). The purified cRNA was then microinjected 
and the recipient cells were stained with the T-antigen anti- 
bodies. As summarized in Table 1, this deletion significantly 
increased the efficiency of Tl-antigen synthesis in terms of 
both the number of Tl-antigen-positive cells and the bright- 
ness of the immunofluorescence staining. 5 h after injection 
about 20-30% of the injected cells exhibited strong intra- 
nuclear Tl-antigen-specific fluorescence after staining with 
the Ab-2 antibody (Table 1). We also stained the injected ceils 
with the HPA-antibody and observed that the deletion of the 
small t-antigen 5' splice site did not significantly affect the 
efficiency of T2-antigen synthesis (Table 1). This observation 
demonstrates that excision of the small t-antigen intron is not 
essential for the nuclear export of the T2-mRNA. Our RT- 
PCR and DNA sequencing experiments confirmed that the 
T2-mRNA still contained the 66 nt small t-antigen intron 
(see below). The high rate of T2-antigen synthesis observed 
after intranuclear microinjection of the cap-Bst/BamA5't- 
cRNA further implies that the small t-antigen intron does 
not affect the translation efficiency of the T2-mRNA. Our 
protein sequencing experiments confirmed that translation of 
both the T2-mRNA and TI-mRNA starts with the large T- 
antigen codon 109 [8]. This AUG is the first potential transla- 
tion initiation signal in the reading frame at these mRNA 
molecules, with a distance of 269 nt to the cap site. There 
are five additional AUGs proximal to the T-antigen codon 
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Fig. 1. (A) Diagram of the early SV40 DNA region from the BglI to the BamHI site, encoding for the large T-antigen (amino acid sequence 
1-708) and small t-antigen (not shown). The amino acid 109 is the first methionine within the second T-antigen exon (amino acid sequence 83- 
708). The small t-antigen 5' and 3' splice sites and the position of the cryptic 5' splice site (amino acids 131-132) are shown. (B) Diagram of 
the pT7-Bst/Bam and pT7-Bst/BamA5't-DNA used for in vitro cRNA synthesis. The binding sites of the primer pair d and h with a genomic 
distance of 258 bp are shown. (C) Schematic illustration of the in-vitro transcripts (Cap-Bst/Bam-cRNA and cap-Bst/BamA5't-cRNA), with the 
small t-antigen intron (66 nt). The shaded box represents he T2-antigen with the amino acid sequence 109-708. (D) Model for the interaction 
of two cRNA molecules during trans-splicing. (E) Schematic structure of the TI-mRNA and Tl-antigen, composed of two segments (amino 
acids 109 131 and 83 708). The t-antigen intron of the cRNA (A) segment is removed after the trans-splicing. With the primer pair d and b 
and the TI-cDNA as template, the PCR generates a 405 bp DNA fragment. 
109 which are immediately followed by termination signals. 
This implies that in monkey and rat cells, the ribosomes can 
and translate these mRNA molecules with a high efficiency 
despite the long untranslated leader sequences. This is not 
unusual, however, since long untranslated leader sequences 
(5' UTR)  are found in about 5-10% of eukaryotic mRNAs,  
for example, in the retinoic-acid-receptor-beta 2 mRNA,  
which has a 461-nucleotide-long 5 'UTR segment [27,28]. 
Synthesis of the T2-antigen also occurred when the cap-Bst/ 
BamA5't-cRNA was microinjected into the cytoplasm of the 
TC7 and rat 2 cells, although at a lower efficiency than after 
nuclear injection (Table 1). However, Tl-antigen synthesis 
was not demonstrable in this case. This was not unexpected, 
since splicing is known to be a nuclear process and cRNA 
molecules are inefficiently transported from the cytoplasm 
into the nuclei of the injected cells, as shown by in-situ hy- 
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Fig. 2. (A) Northern blot analysis: (lane 1) the in vitro synthesized 
2.2 kb cap-Bst/BamA5't-cRNA; (M) RNA size marker (Promega). 
(B) PCR analysis of the cap-Bst/BamA5't-cRNA: (lane 1) PCR 
without reverse transcription (RT) to exclude template DNA con- 
tamination; (lane 2) PCR with prior RT of the cRNA (RT-PCR); 
(M) DNA size marker (BRL). 
bridization experiments (M. Graessmann, personal observa- 
tion). 
The aim of the second set of microinjection experiments 
was to demonstrate trans-splicing directly on the level of 
T I -mRNA synthesis by means of RT-PCR analysis. For 
this, 100 TC7 cells were microinjected with the cap-Bst/ 
BamA5't-cRNA and 3 h later the RNA was extracted, con- 
verted into cDNA and PCR-amplified with the SV40-specific 
primer pair d and b. These primers bind upstream and down- 
stream from the 5' cryptic splice site (Fig. 1), respectively. 
With this primer pair it is possible to differentiate between 
the unprocessed cRNA (or T2-mRNA) and the 147 nt larger 
trans-spliced T I -mRNA.  With the unprocessed cRNA as tem- 
plate, the RT-PCR generates a 258 bp DNA segment (Fig. 
1C); with the T I -mRNA as template it generates a 405 bp 
DNA segment (Fig. 1E). As shown in Fig. 3, lane 3, with the 
RNA re-extracted from the microinjected TC7 cells the RT- 
PCR generated both the 258 bp and the 405 bp DNA seg- 
ments (the exact sizes of the PCR products were determined 
by DNA sequencing as shown below). 
We repeated the microinjection with the cap-Bst/Bam 
cRNA,  which still contained the intact small t-antigen intron. 
As shown in Fig. 3, lane 2, the amount of the 405 bp RT-PCR 
cap-Bst /Bam-cRNA. - - .  • 
cap-Bst/BamA5't-cRNA • • 
Nuc le i , - - .  • Q- -  
Injection into 
Cytopl., - -  • • 
405  -----  
258 ~ 
1 2 3 4 
Fig. 3. RT-PCR analysis: (lane l) RNA extracted from mock in- 
jected TC7 cells RNA; (lane 2) RNA extracted from TC7 cells 3 h 
after intranuclear injection of the cap-Bst/Bam-cRNA; (lane 3) 
RNA extracted from TC7 cells 3 h after intranuclear injection of 
the cap-Bst/BamA5't-cRNA; (lane 4) RNA extracted from TC7 cells 
3 h after cytoplasmic injection of the cap-Bst/BamA5't-cRNA. The 
RT-PCR products were separated by agarose gel electrophoresis 
and subjected to Southern blot analysis. The blot was hybridized 
with the early SV40 Bgl/Bam DNA fragment. The 405 bp PCR 
product was obtained from the TI-mRNA, the 258 bp segment was 
generated from the T2-mRNA or respectively from the unprocessed 
cRNA. 
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Fig. 4. RT-PCR analysis: (lanes l 7) RNA re-extracted from TC7 
cells at different points in time (0 6.5 h) after nuclear injection of 
the cap-Bst/BamA5't-cRNA; (lane 8) RNA isolated from the 
14A5't/7 cell. Each test point is based on 100 microinjected TC7 
cells. The RT-PCR products were separated an agarose gel and sub- 
jected to Southern blot analysis as described in Fig. 3. 
Table l 
Percentage of T-antigen positive cells 
Cells injected with Injected into Percentage of T-antigen positive cells 
HPA-stained Ab-2-stained 
cap-Bst/Bam-cRNA nuclei 50 60 3 5 
cap-Bst/BamA5't-cRNA nuclei 50 60 20 30 
cap-Bst/BamA5't-cRNA cytoplasm 20-30 0 
TC7 cells microinjected with cRNA molecules were fixed and stained for SV40 T-antigen 6 h later. The hamster polyclonal antiserum (HPA) allows 
detection of both the T2- and Tl-antigens, whereas the mouse monoclonal antibody Ab-2 exclusively monitors Tl-antigen. The wt SV40 T-antigen 
is recognized by both types of antisera. 
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Primer d m 258 nt • Primer b 
GAA ATG CCA TCT AGT GAT GAT . . . . . . .  ~G GTA GA~ . . . .  AGG CAT AAC AGT TAT AAT CAT AAC 
Met Pro Set Ser Asp Asp Lys Val GIU Arg His ASh Set Tyr ASh His ASh 
109 131 132 
T2 cDNA 
(258 nt PCR DNA)  
Primer d P - -258+147 nt . . . .  • Primer b 
GAA ATG CCA TCT AGT GAT CAT . . . .  AAG GTA G~ . . . .  AGG CAT AAC AGT TAT AAT CAT AAC 
109Met Pro Ser Set Asp Asp L y s l ~  I Va1132 Glu Arg His Asn Set Tyr Asn His Asn 
S~l ~ ~ '~ 
XTT CC~ •ec . . . . . . . . . . . .  ~c,~ ~ (405 nt PCR DNA)  
Ile Pro Thr Arg Lys 
83 131 
Fig. 5. (A) Nucleotide (nt) sequence of the 258 bp RT-PCR product obtained from the T2-mRNA. The nucleotide sequence is exactly the wt 
SV40 DNA nucleotide sequence 44964239. The positions of the primers d and b are indicated. The frame shows the cryptic 5' splice site and 
the corresponding amino acid sequence. (B) Nucleotide sequence of the 405 bp RT-PCR product obtained from the TI-mRNA. This fragment 
contains the same sequence as the 258 bp DNA fragment and a 147 nt 'insertion' between t 4425 and 4424 (amino acids 131/132). This 147 
nt segment corresponds to the wt SV40 nt sequence 4571M425 encoding for the large T-antigen amino acid sequence 83 131. 
DNA segment synthesized was significantly lower than that 
obtained after microinjection of the cap-Bst/BamA5't-cRNA, 
confirming that small t-antigen cis-splicing and T I -mRNA 
trans-splicing are in competition with each other. The RT- 
PCR analysis further confirmed the above observation that 
T I -mRNA synthesis requires that the cRNA molecules be 
microinjected into the nuclei of the recipient cells. Following 
cytoplasmic microinjection, the RT-PCR generated only the 
258 bp DNA fragment (Fig. 3, lane 4). 
To determine more precisely when trans-splicing occurs 
after microinjection of the cap-Bst/BamA5't-cRNA, the TC7 
cells were lysed at different points in time and the cRNA was 
re-extracted and subjected to RT-PCR analysis. As shown in 
Fig. 4, trans-splicing was already demonstrable 0.5 h after 
cRNA injection and the maximal trans-splice reaction oc- 
curred 1 2 h later. At this time about 10 20% of the injected 
cRNA molecules were converted into T I -mRNA by trans- 
splicing (Fig. 4). 
Finally, we cloned and sequenced the SV40-specific PCR 
products. These experiments revealed that the 258 bp segment 
corresponded exactly to the wt SV40 DNA sequence 4496 
4239 (Fig. 5A). The 405 bp segment contained the same se- 
quence and an additional 147 bp segment (4571M425) be- 
tween nt positions 4425 and 4424 (cryptic 5' splice site; T- 
antigen amino acids 1311132). These 147 bp encode for the wt 
large T-antigen amino acid sequence 83 131, as indicated in 
Fig. 5B. We also repeated the RT-PCR analysis with primers 
which bind downstream and upstream from the small t-anti- 
gen intron, as described elsewhere [8]. This and subsequent 
DNA sequencing experiments confirmed that the T1- and 
T2-mRNA still contained the small t-antigen intron with the 
5' donor splice site mutated (data not shown). 
3.3. The cryptic 5' splice site is essential for trans-splicing 
In the model shown in Fig. 1 D we propose that trans-splice 
and cis-splice mechanisms are closely related and that mam- 
malian cells utilize the same splicing machinery for both path- 
ways. With two cap-Bst/BamA5't-cRNA molecules as precur- 
sors, trans-splicing is favored because the cryptic 5' splice site 
of the donor cRNA (A) is not followed by a functional 3' 
splice site, and the 3' splice site at the acceptor cRNA mole- 
cule (B) is not removable by small t-antigen c/s-splicing. Con- 
sequently, trans-splicing should not occur when the cryptic 5' 
splice site is not accessible. To demonstrate this, the G/GTA 
splice consensus equence [29] of the cryptic 5' splice at the 
p14 DNA (it contains the SV40 Bst/Bam fragment and the 
early SV40 promoter [8]) was converted into G/CTT by site- 
directed mutagenesis, generating the pl4Acry5' DNA. The 
pl4Acry5' DNA was then transfected into rat 2 cells and 
different independent T-antigen positive cells lines were iso- 
lated and further analyzed. As shown by RT-PCR analysis 
and by immunofluorescence staining, cells of all lines synthe- 
sized the T2-mRNA and the T2-antigen exclusively. DNA 
sequencing confirmed that the T-antigen amino acid 132 of 
this T2-antigen was converted from Val to Leu. Generation of 
the T I -mRNA was not demonstrable in any of the analyzed 
cells. 
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